Immunotherapy When You Already Have COPD or Fibrosis — Higher Risk, Not a Rule-Out

It can be — and with less lung reserve to begin with, the safe margin is smaller than for someone without pre-existing lung disease. Any breathlessness that is new, clearly worse than your usual pattern, or does not settle the way it normally does needs same-day assessment, not a wait-and-see approach.

There is no safe home-management step for a breathing symptom that is new or worse than your baseline once you're on immunotherapy — not an extra dose of your usual inhaler tried alone, not "waiting to see if it settles overnight." The correct response is always to get it checked the same day, or go to the ER for the emergency signs above.

Yes. Pre-existing lung disease is recognised in NCCN and ASCO guidance on immune-related adverse events as a factor linked to a higher chance of clinically significant immune pneumonitis, and to a smaller reserve for absorbing that inflammation without symptoms worsening quickly. This is one reason India's large burden of COPD and post-tuberculosis or fibrotic lung disease — common after years of smoking, biomass-fuel smoke exposure, or old TB scarring — has had almost no dedicated patient guidance until now.

In many cases, yes. Pre-existing COPD or interstitial lung disease is not an automatic reason to withhold immunotherapy — it is one factor your oncology team weighs against the expected benefit of the treatment for your cancer, alongside how severe your lung disease is and how stable it has been recently. This is an individual decision made with a pulmonologist involved, not a fixed rule that applies to everyone with a lung comorbidity.

Very severe or unstable lung disease — for example needing continuous home oxygen, or a fibrosis pattern that has been rapidly worsening — can shift that balance, and a small number of patients are advised against immunotherapy or towards a different treatment plan for this reason. That decision is made case by case by your tumour board, never assumed from a diagnosis label alone.

Most patients with pre-existing lung disease get a baseline breathing test, a baseline oxygen reading, and a chest scan before immunotherapy starts, followed by closer review visits and home oxygen tracking through treatment. The goal is a clear "before" picture so a real change is caught early, distinguished from your usual COPD or fibrosis pattern rather than confused with it.

1. 1

   Baseline breathing tests

   Spirometry, and sometimes a DLCO (gas transfer) measurement, records your lung function before treatment starts, giving your team a personal baseline rather than a generic normal range.

2. 2

   Baseline oxygen and chest scan

   A resting oxygen saturation reading and a chest CT or X-ray are recorded before the first dose, so any later scan or reading is compared against your own starting point, not a healthy-lung average.

3. 3

   More frequent review visits

   Patients with COPD or fibrosis are typically seen and questioned about breathing symptoms more often than patients without lung comorbidities, especially in the first few cycles.

4. 4

   Home pulse oximeter tracking

   Many patients are asked to check and log their oxygen saturation at home between visits — see our companion page, Using a Home Pulse Oximeter During Immunotherapy, for how to do this correctly.

5. 5

   A lower threshold for pausing treatment

   If any new or worse-than-baseline respiratory symptom appears, the threshold for pausing immunotherapy and investigating is set lower than for a patient without pre-existing lung disease.

Immune pneumonitis can move from mild breathlessness on exertion to breathlessness at rest within days once lung inflammation is established, and that progression can be faster and harder to buffer when baseline lung function is already reduced by COPD or fibrosis. This is why any new or worse-than-usual chest symptom is reported the same day, never tracked for a few days to see if it settles.

This is one reason immune pneumonitis in patients with COPD or fibrosis sits among the highest harm-prevention priorities in immunotherapy care — a change that looks like "just a bad COPD day" can need a completely different, time-sensitive response.

These companion pages go deeper into specific parts of the same lung and breathing irAE pathway — worth bookmarking alongside this one.

• Using a Home Pulse Oximeter During Immunotherapy — how to track your oxygen levels correctly between review visits.
• Tuberculosis Risk and Immunotherapy in India — relevant if your lung scarring is TB-related, a common overlap with COPD in India.
• Can Immunotherapy Be Restarted After Pneumonitis? — what happens after a pneumonitis episode is treated and how a restart decision is made.
• Immune Pneumonitis: Cough and Breathlessness on Immunotherapy — the general symptom picture this page builds on.
• Immunotherapy at CION Cancer Clinics — how we monitor and support patients through immune-related side effects, from the first infusion onward.

Lung Comorbidities Are Manageable When Monitoring Starts Before Treatment

Patients with COPD or fibrosis who have a clear baseline and report changes promptly are supported by the same multidisciplinary team throughout treatment.